Khosrow Adeli, Ph.D., FCACB, NACB, DABCC
Dr. Adeli is currently head and full professor of Clinical Biochemistry at the Hospital for Sick Children and the Departments of Biochemistry, and Laboratory Medicine & Pathobiology at the University of Toronto in Toronto, Canada. He is also the Director of Point of Care Testing program at the Hospital for Sick Children in Toronto. Dr. Adeli is a fellow of the Canadian Academy of Clinical Biochemistry and a diplomate of the American Board of Clinical Biochemistry. Dr. Adeli served as the Editor-in-Chief of the Clinical Biochemistry journal for 7 years (1999-2006). He is an editorial board member of the Clinical Biochemist Reviews. He served (2006-2010) as the President of COMACC , the Commission on Accreditation in Clinical Chemistry, a North American organization responsible for accreditation of clinical chemistry training programs in the USA and Canada. He currently serves as the Vice-Chair of Publications and Communications Division of the International Federation of Clinical Chemistry (IFCC), as well as the Public Relations Coordinator for the IFCC organization.
He has been actively involved in both basic and clinical laboratory research since 1988 and has published over 200 articles and abstracts to date. He has received several national and international awards for research excellence including the Merck Senior Investigator Award of the Canadian Lipoprotein Conference (2008), the Canadian Society of Clinical Chemistry National Award for outstanding contributions to clinical chemistry (2006), Canadian Academy of Clinical Biochemistry National Award (2004), the Canadian Society of Clinical Chemistry Research Excellence Award (1999), Bristol-Meyers Squib Young Investigator (1995), the Merck Senior Investigator Award (1997), and the Simon-Pierre Noel Award (2001) from the Canadian Lipoprotein Conference.
His basic research program is focused on the link between insulin resistant diabetes and dysregulation of lipoprotein metabolism. His group has particularly focused on elucidating the molecular mechanisms linking diet-induced insulin resistance and metabolic dyslipidemia. His laboratory is employing animal models of insulin resistance to investigate the molecular mechanisms mediating the diabetogenic effect of fructose-rich diets, mechanisms of fructose-induced hepatic insulin resistance, and pathways leading to hepatic and intestinal lipogenesis and lipoprotein dysregulation. Dr. Adeli holds research operating grants from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), the Heart and Stroke Foundation of Ontario, Merck, AstraZeneca, Pfizer, Abbott Diagnostics, Roche Diagnostics, Resverlogix, and Amgen.
Dr. Adeli is also active in clinical chemistry research and has been involved in a number of projects on diagnostic test development projects. He is the principal investigator of the CALIPER (Canadian Laboratory Initiative on Pediatric Reference Interval Database) project aimed at the establishment of a laboratory reference interval database for biomarkers of pediatric disease. This is a national initiative involving a network of several clinical laboratory investigators from pediatric health care centers from across Canada. Standardized age- and gender-specific reference intervals are being established involving pediatric health care centers across Canada. This valuable database will also be useful to pediatric health care centers worldwide as significant gaps exist in the available database in both developed and developing countries.